anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
The invention relates to the use of one or more phyllanthus constituent(s) or substances or substance mixtures obtained therefrom for preventing or treating infection diseases, which are caused by viruses of the family of Flaviviridae or which are involved in the development or progression of viruses of the family of Flaviviridae. The invention also relates to the use of one or more phyllanthus constituent(s) or substances or substance mixtures obtained therefrom for producing a medicament used in the prevention or treatment of infectious diseases, which are caused by viruses of the family of Flaviviridae or which are involved in the development or progression of viruses of the family of Flaviviridae. The invention additionally relates to the use of one or more phyllanthus constituent(s) or substances or substance mixtures obtained therefrom for inhibiting the multiplication of viruses of the family of Flaviviridae. A method is also disclosed for preventing or treating infectious diseases in a mammal, which are caused by viruses of the family of Flaviviridae or which are involved in the development or progression of viruses of the family of Flaviviridae, whereby one or more phyllanthus constituent(s) or substances or substance mixtures obtained therefrom is/are administered to the mammal. Additionally disclosed is a method for inhibiting the multiplication of viruses of the family of Flaviviridae, whereby one or more phyllanthus constituent(s) or substances or substance mixtures obtained therefrom is/are brought into contact with the viruses. A preferred virus is the hepatitis C virus.
Previous studies have shown that topiramate is effective in preventing migraine headaches. This study will start with a 4-week baseline period in which no treatment is given, followed by a 26-week period in which each patient's dose is adjusted and then kept stable for 4 weeks. The dose will start at 25 milligrams of topiramate per day and will be increased 25 milligrams per day once weekly and then raised to either the target--100 milligrams per day--or the maximum dose that is well tolerated up to 200 milligrams per day. Patients randomized to receive topiramate will remain on that dose. The comparison phase of the study is a 26-week period in which the change in migraine days of patients on topiramate (taking at least 50 milligrams per day) is compared with the change in migraine days for patients on the placebo. Also studied will be the patients' health-related quality of life as assessed by questionnaires filled out at specific visits as well as the patients' views of the safety and tolerability of topiramate. The study hypothesis is that the number of migraine days, periods, and attacks during the last 4 weeks of the double-blind phase, relative to the last 4 weeks of the open-label phase, is reduced more in the topiramate group than the placebo group. During open-label (26-weeks) and double-blind phase (26-weeks), patients receiving topiramate will take 25 milligrams to 100 milligrams daily by mouth; increased by 25 milligrams per day once weekly; dose cannot exceed 200 milligrams per day and must be stable for the last 4 weeks.
All tetracyclines form a stable calcium complex in any bone-forming tissue. A decrease in fibula growth rate has been observed in premature human infants given oral tetracycline in doses of 25 mg/kg every 6 hours. This reaction was shown to be reversible when the drug was discontinued. The safety and effectiveness of MINOLIRA have not been established in patients less than 12 years of age [see Use in Specific Populations (8.1, 8.4)].

Results of animal studies indicate that tetracyclines cross the placenta, are found in fetal tissues, and can cause retardation of skeletal development on the developing fetus. Evidence of embryotoxicity has been noted in animals treated early in pregnancy [see Use in Specific Populations (8.1)].
Clindamycin in 5% Dextrose Injection in the Cryovac plastic container for intravenous use is composed of clindamycin phosphate equivalent to 300, 600 and 900 mg of clindamycin premixed with 5% dextrose as a sterile solution. Disodium edetate has been added at a concentration of 0.04 mg/mL. The pH has been adjusted with sodium hydroxide and/or hydrochloric acid. Clindamycin is a semisynthetic antibiotic produced by a 7(S)-chloro-substitution of the 7(R)-hydroxyl group of the parent compound lincomycin.

The chemical name of clindamycin phosphate is L-threo-α-D-galacto\- Octopyranoside, methyl-7-chloro-6,7,8-trideoxy-6-[[(1-methyl-4-propyl-2- pyrrolidinyl) carbonyl] amino]-1-thio-, 2-(dihydrogen phosphate), (2S-trans)-.

The molecular formula is C18H34CIN208PS and the molecular weight is 504.97.

The structural formula is represented below:

The plastic container is fabricated from a specially designed multilayer plastic, M312A material. Solutions in contact with the plastic container can leach out certain of its chemical components in very small amounts within the expiration period. The suitability of the plastic has been confirmed in tests in animals according to the USP biological tests for plastic containers, as well as by tissue culture toxicity studies.
Intellectual disability (ID) is defined by the combination of an intelligence quotient (IQ) of less than 70 and significant limitations in adaptive functioning in various areas, with onset before the age of 18. Although common (2% of the population), ID is an extremely heterogeneous condition in terms of severity, associated additional disabilities and aetiologies. Until recently, it was reported that 25% of IDs had an acquired cause (perinatal anoxia, infection, etc.), 25% a genetic cause, and 50% an 'undetermined' cause; advances in genetic diagnosis are gradually reducing the latter proportion in favour of genetic aetiologies. The rarity of each of the genetic causes of ID and the lack of specificity of most of the syndromes mean that it is often difficult to make an aetiological diagnosis.

This is a descriptive, retrospective and prospective study that aim to include 1000 patients across 10 centres aged over 20 years old on consultation between 2016 to 2025 who have been informed (where applicable, the guardian), who have not oppose to participate and who meet the inclusion and non-inclusion criteria. The first stage of the study will be the selection of patients' medical records by the participating centres. Patients aged over 20 with a proven intellectual disability who have been seen for consultations since 2016 will be identified on the basis of their electronic and/or paper medical records (retrospetive). Selection of the file includes a check of the elements present and missing from the file, using a clinical data collection grid and genetic results. If the data is available, the patient will then be selected. Once the files have been selected, the patient or, where appropriate, the guardian (if the patient is under guardianship) will be informed individually of the study and asked for their non opposition. For the prospective arm, patients over the age of 20 with a proven intellectual disability who are seen for routine care in the participating centres will be included. Each centre will increment a patient identification number for pseudonymisation of reports. A name correspondence table will be maintained by each center to establish a link between the research identifier and the participant's identity. Each table will be stored on each centre's secure server. The anonymized reports will be transmitted to the coordinating team through the secure Dispose platform, which will transfer all the participants' data to a REDCap APHP database.

Descriptive statistic will be performed to count the number of patients with the same genetic syndrome. The age of onset of comorbidities and the percentage of each complication per syndrome will be calculated for all patients, including the means and median.
Glycolysis occurs in all living organisms as a form of energy supply. Pyruvate kinase M2 (PKM2) is one of the rate‑limiting enzymes in the glycolytic process. PKM2 is considered to serve an important role in several terminal diseases, including sepsis. However, to the best of our knowledge, the specific mechanistic role of PKM2 in sepsis remains to be systematically summarised. Therefore, the present review aims to summarise the roles of PKM2 in sepsis progression. In addition, potential treatment strategies for patients with sepsis are discussed. The present review hopes to lay the groundwork for studying the role of PKM2 and developing therapeutic strategies against metabolic disorders that occur during sepsis.
Technetium Tc 99m contributes to a patient’s overall long-term cumulative radiation exposure. Long-term cumulative radiation exposure is associated with an increased risk of cancer. Ensure safe handling and preparation procedures to protect patients and health care workers from unintentional radiation exposure. Use the lowest dose of Technetium Tc 99m pentetate necessary for imaging. Encourage patients to drink fluids and void as frequently as possible after intravenous administration [see Dosage and Administration (2.1, 2.3)].

Radiation risks associated with the use of Technetium Tc 99m pentetate are greater in pediatric patients than in adults due to greater radiosensitivity and longer life expectancy.
Use Aseptic Technique – Not for Direct Infusion

The pharmacy bulk package is for use in a Pharmacy Admixture Service only.

  1. During use, container must be stored and all manipulations performed in an appropriate laminar flow hood.
  2. Remove cover from container and cleanse closure with antiseptic.
  3. A single entry through the vial closure should be made with a sterile dispensing set which allows measured dispensing of the contents. Transfer individual dose(s) to appropriate intravenous infusion solutions without delay. Use of a syringe with needle is not recommended as it may cause leakage. Multiple entries will also increase the potential of microbial and particulate contamination. The above process should be carried out under a laminar flow hood using aseptic technique. ANY UNUSED PORTION MUST BE DISCARDED WITHIN 4 HOURS.
  4. Parenteral drug products should be inspected visually for particulate matter and discoloration prior to administration, whenever solution and container permit.
Platelets are anucleated cells that circulate in the bloodstream. Historically, platelets were thought to perform a singular function-stop bleeding via clotting. Although platelets do play a key role in hemostasis and thrombosis, recent studies indicate that platelets also modulate inflammation, and this platelet-induced inflammation contributes to the pathophysiology of various diseases such as atherosclerosis and diabetes mellitus. Thus, in recent years, our understanding of platelet function has broadened. In this review, we revisit the classic role of platelets in hemostasis and thrombosis and describe the newly recognized function of platelets in modulating inflammation. We cover the potential use of purinergic receptor antagonists to prevent platelet-modulated inflammation, particularly in patients with chronic kidney disease, and finally, we define key questions that must be addressed to understand how platelet-modulated inflammation contributes to the pathophysiology of chronic kidney disease.
In Session 1, subjects will receive a single oral dose of SB-773812 20 milligrams (mg), followed by 21 days-washout. In Session 2, subjects will receive once daily oral dose of ketoconazole 400 mg repeated for 8 days. On day 5, single oral dose of SB-773812 20 mg will be dosed concomitantly with ketoconazole.
At the completion of the subjects surgery but prior to awakening from anesthesia, 80mg of gentamicin in 50 mL of normal saline will be infused into the subject's bladder through the standard-of-care transurethral catheter by the surgeon. The surgeon will then clamp the catheter and label the catheter with the clamping time. The catheter will be clamped to prevent the gentamicin from immediately flowing out of the bladder and thus allow the gentamicin time to have an effect. The subject will then proceed as usual to the postoperative anesthesia care unit. A member of the subject's care team will unclamp the catheter after 1 hour. The subject will otherwise have usual pre-operative and post-operative care.
Individuals with type 2 diabetes (T2D) show signs of low-grade inflammation, which is related to the development of insulin resistance and beta-cell dysfunction. However, the underlying triggers remain unknown. The gut microbiota is a plausible source as it comprises pro-inflammatory bacteria, bacterial metabolites and viruses, including (bacterio)phages. These prokaryotic viruses have been shown to mediate inflammatory responses in gastrointestinal disease. Given the differences in phage populations in healthy individuals versus those with cardiometabolic diseases such as T2D, we here questioned whether phages from T2D individuals would have increased immunogenic potential. To address this, we isolated intestinal phages from a fresh stool sample of healthy controls and individuals with newly diagnosed, treatment-naive T2D. Phages were purified using cesium chloride ultracentrifugation and incubated with healthy donor dendritic cells (DCs) and autologous T cells. Donors with T2D had slightly higher free viral particle numbers compared to healthy controls (p = .1972), which has been previously associated with disease states. Further, phages from T2D induced a higher inflammatory response in DCs and T cells than phages from HC. For example, the expression of the co-stimulatory molecule CD86 on DCs (p < .001) and interferon-y secretion from T cells (p < .01) were increased when comparing the two groups. These results suggest that phages might play a role in low-grade inflammation in T2D individuals.
The present invention relates to a chewing gum production method and chewing gum produced by the production method. The production method is realized by adding a physiological refrigerant, such as acyclic formamide or the combination of physiological refrigerants. In the first implementing scheme, the combination of physiological refrigerants is made to be in the structure of improvement release, the combination of the improvement release/ refrigerants is obtained by physically improving the performance of the combination of refrigerants by preferablely coating, drying, etc., when added to chewing gum, the granules are suitable for strengthening the shelf life and stability of flavouring agents, and /or the improved release property of the chewing gum is obtained when the chewing gum is chewed. In the second implementing scheme, physiological refrigerants, menthol and menthone exist together. In the third implementing scheme, the coating chewing gum has a coating containing physiological refrigerants. The chewing gum optimized by the present invention provides high flavour effect, and reduces or eliminates pungent and astringent sensation which usually exists under the condition of high flavour effect. In addition, the chewing gum optimized by the present invention provides purified, high quality refreshing chewing gum coated with xylitol or other polyatomic alcohols, wherein the concentration of the xylitol is reduced or the xylitol is canceled.
The majority of cases of undifferentiated acute febrile illness (AFI) in the tropics have an undefined etiology. In Thailand, AFI accounts for two-thirds of illnesses reported to the Ministry of Public Health. To characterize the bacterial and viral causes of these AFIs, we conducted molecular pathogen screening and serological analyses in patients who sought treatment in Chum Phae Hospital, Khon Kaen province, during the period from 2015 to 2016. Through integrated approaches, we successfully identified the etiology in 25.5% of cases, with dengue virus infection being the most common cause, noted in 17% of the study population, followed by scrub typhus in 3.8% and rickettsioses in 6.8%. Further investigations targeting viruses in patients revealed the presence of Guadeloupe mosquito virus (GMV) in four patients without other pathogen co-infections. The characterization of four complete genome sequences of GMV amplified from AFI patients showed a 93-97% nucleotide sequence identity with GMV previously reported in mosquitoes. Nucleotide substitutions resulted in amino acid differences between GMV amplified from AFI patients and mosquitoes, observed in 37 positions. However, these changes had undergone purifying selection pressure and potentially had a minimal impact on protein function. Our study suggests that the GMV strains identified in the AFI patients are relatively similar to those previously reported in mosquitoes, highlighting their potential role associated with febrile illness.
About 35% of veterans are obese. The MOVE! program is a nation-wide 8-week program of group classes nationally to help obese veterans lose weight. While the program is successful for some veterans, about 75% of veterans are unable to lose ≥5% of their weight 24 weeks after MOVE! New methods are needed to help obese veterans seeking weight loss. Using personalized genomic information dictating a specific diet, and information on exercise and eating behaviors, may be one means to help promote weight loss. Just a single nucleotide change or polymorphism (SNP) in a gene can increase a person's risk for obesity, or change their lipid profile in response to the consumption of different macronutrients such as of fats or carbohydrates. Over 54 genetic loci have been associated with obesity phenotypes and clinical studies are now reporting associations between SNPs and/or functional alterations of gene expression (epigenetics) and the ability to lose weight or not. We will implement a randomized clinical trial to test a set of genomic data called the FIT™ test (Pathway Genomics™) containing information on SNPs that affect obesity risk, confer specific diet recommendations, outline eating behaviors and suggest responses to various exercise regimens. The overall goal of this project is to evaluate if this supplemental genetic information with a genomically-derived diet built around packaged meals to improve adherence, in parallel with the MOVE! program at the VA in San Diego, will promote weight loss in more obese veterans than those receiving usual care and eating diets based around packaged meals. Our primary hypotheses are that more obese veterans in the MOVE! program will lose 5% of their weight if they receive personalized genomic information and a genomically-derived diet built around packaged meals when compared to veterans in the same program that receive usual care during MOVE! and packaged meals after 8 or 24 weeks. We also hypothesize that more veterans in the genomic group that lose 5% weight loss at 8 weeks will maintain this weight loss after 24 weeks compared to veterans in the usual care group.
PURPOSE: To obtain a new emulsifier which has low skin-irritating properties, is suitable for cosmetics, and exhibits excellent emulsifying characteristics in the absence of any other emulsifier. CONSTITUTION: This emulsifier comprises a higher fatty acid dextrin formed by introducing a 10-24C satd. fatty acid into dextrin having an average degree of saccharide polymn. of 5-150 or into a reduced dextrin having an average degree of saccharide polymn. of 5-150 in an amt. of the fatty acid of 1.2-2.0 units based on a saccharide unit. The emulsion compsn. contains 0.5-15% emulsifier of the invention and does not contain any other emulsifier. The cosmetic contains the compsn.
BACKGROUND: The number of known inherited metabolic diseases (IMDs) has been expanding, and the rate of diagnosis is improving with the development of innovative approaches including next generation sequencing (NGS). However, a substantial proportion of IMDs remain undetected by traditional diagnostic approaches. We aim to highlight the spectrum of IMDs diagnosed by the Undiagnosed Diseases Network (UDN) and to learn from the UDN diagnostic processes that were able to detect IMDs.
METHODS: We conducted a retrospective analysis of 757 UDN participants diagnosed from 2015 until 2023 using the cohort database, which were divided into a cohort with IMDs (n = 194; 27%) and a cohort whose phenotypes were not explained by an IMD (n = 563; 73%), based on the International Classification of Inherited Metabolic Disorders (ICIMD). Then, we divided the causes of the metabolic 194 diagnoses into seven groups that included all the ICIMD categories. We inspected which clinical and laboratory approaches contributed to a final UDN diagnosis. We also present a UDN case example from each group to highlight the diagnostic yields that resulted from combining newer diagnostic approaches in the UDN and illustrate potential pitfalls of current NGS methods.
RESULTS: These 194 cases of IMDs included examples from 21/25 (84%) of the ICIMD categories. Of the UDN subjects 164/194 (85%) were diagnosed with IMDs through NGS.
CONCLUSION: The spectrum of IMDs detected in the UDN cohort is large and growing and appropriate use of newer multiple diagnostic approaches should further increase diagnosis of IMDs that are presently missed by the traditional laboratory screening methods.
Training type 1 will be administered in the first part of the crossover trial and Training type 2 will be administered in the second part of the trial. Each training part consists of 20 twenty-minute long sessions with the recommended frequency of 2 sessions per work day. Thus each training part can be completed in 10 work days (2 weeks).
An apparatus, system, and method create an operational Personal Health Record (PHR). The PHR server maintains a PHR of the owner, the PHR including a plurality of portions, one of the portions being an aggregated portion including a plurality of sub-portions, one of the sub-portions corresponding to a healthcare entity. The method includes receiving a retrieval input from the owner of the PHR, the retrieval input identifying the healthcare entity from which information is to be requested. The method includes generating a request for the information. The method includes sending the request to the healthcare entity. The method includes receiving the information from the healthcare entity. The method includes including the information in the sub-portion of the aggregated portion in the PHR that corresponds to the healthcare entity.